Metabolic Dysfunction-Associated Steatohepatitis Drugs Market to Grow at 18.1% CAGR, Reaching USD 929.05 million by 2033 | DataM Intelligence

The global Metabolic Dysfunction-Associated Steatohepatitis Drugs Market size reached USD 180.1 million in 2024 and is projected to reach USD 929.05 million by 2033, growing at a CAGR of 18.1% during the forecast period 2025-2033, according to DataM Intelligence.

United States: Recent Industry Developments

✅ In October 2025, Madrigal Pharmaceuticals received FDA accelerated approval for resmetirom, the first targeted therapy for MASH with liver fibrosis.
✅ In October 2025, Novo Nordisk initiated a Phase III clinical trial combining semaglutide with a novel FXR agonist for synergistic MASH treatment.
✅ In October 2025, the NIH allocated USD 150 million for research on non-invasive MASH diagnostics and novel therapeutic targets.

Japan: Recent Industry Developments

✅ In October 2025, Takeda Pharmaceutical entered a strategic collaboration to develop a novel PPAR agonist for MASH treatment in Asian populations.
✅ In October 2025, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) established expedited review pathways for MASH therapies.
✅ In October 2025, Mitsubishi Tanabe Pharma launched a large-scale biomarker discovery program for MASH progression and treatment response.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market?jd

Market Trends & Drivers

The MASH Drugs Market is experiencing rapid growth driven by the increasing global prevalence of metabolic syndrome, rising obesity rates, and growing awareness of liver disease progression. Key trends include the development of combination therapies, advancement of non-invasive diagnostics, and targeted approaches addressing specific metabolic pathways. The significant unmet medical need, improving regulatory pathways, and expanding treatment guidelines are significantly accelerating market development.

Competitive Landscape

The market features intense competition among pharmaceutical companies, biotechnology firms, and research institutions.

Madrigal Pharmaceuticals, Inc. leads with resmetirom, the first FDA-approved therapy for MASH with liver fibrosis.
Intercept Pharmaceuticals, Inc. pioneers FXR agonist development with obeticholic acid for MASH treatment.
Novo Nordisk A/S leverages GLP-1 receptor agonist expertise for metabolic dysfunction management in MASH.
Pfizer Inc. advances multiple pipeline candidates targeting inflammatory and fibrotic pathways in MASH.
Bristol-Myers Squibb Company develops novel combinations addressing metabolic, inflammatory, and fibrotic components.
Takeda Pharmaceutical Company Limited focuses on Asian-specific MASH therapies and combination approaches.
Galmed Pharmaceuticals Ltd. specializes in liver-targeted therapies for metabolic liver diseases.
Viking Therapeutics, Inc. develops selective thyroid hormone receptor beta agonists for MASH treatment.
89bio, Inc. advances FGF21 analog therapy for metabolic dysfunction-associated conditions.
Sagimet Biosciences Inc. focuses on FASN inhibitors for de novo lipogenesis reduction in MASH.

Segmentation

By Disease Stage [Intraoral X-ray, Extraoral X-ray, Imaging Software, Others]
By Medication [2D Digital Radiography, 3D CBCT, Optical/Impression Scanners, Digital Sensors, Hybrid Systems]
By Route of Administration [Endodontics, Implantology, Orthodontics, Oral & Maxillofacial Surgery, Others]

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/metabolic-dysfunction-associated-steatohepatitis-mash-drugs-market?jd

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
⇥ Asia-Pacific (Japan, China, India, South Korea, Australia, Rest of Asia Pacific)
⇥ South America (Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
At DataM Intelligence, we provide more than just data-we deliver end-to-end business solutions. From deep-dive research to strategic consulting, we partner with you to turn complex market trends into a clear competitive advantage.
Leveraging our extensive database of 6,300+ reports across 40+ domains, we offer the insights and astute recommendations you need to make confident decisions. We are proud to support 200+ companies worldwide in navigating their key business challenges and accelerating their growth trajectory.

This release was published on openPR.